<DOC>
	<DOCNO>NCT01703078</DOCNO>
	<brief_summary>The purpose study determine new ingenol derivative gel safe well tolerate ingenol mebutate gel apply AK lesion forearm two consecutive day .</brief_summary>
	<brief_title>Safety Tolerability Different Concentrations Ingenol Derivative Field Therapy Treatment Actinic Keratosis</brief_title>
	<detailed_description>Various concentration new ingenol derivative apply AKs forearm . Reactions safety compare US register market ingenol gel ascertain new ingenol least safe well tolerate register ingenol .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Must male female least 18 year age . Female patient must nonchildbearing potential childbearing potential negative serum urine pregnancy test use effective contraception Ability provide inform consent location select treatment area within 5cm incompletely heal wound within 5cm suspect basal cell carcinoma squamous cell carcinoma undergone Cosmetic therapeutic procedure within 2cm selected treatment area 2 week prior Visit 2 use acidcontaining therapeutic product within 2cm selected treatment area 2 week prior Visit 2 use topical moisturisers/creams/lotions , artificial tanner topical steroid within 2cm select treatment area 2 week prior visit 2 Treatment immunomodulators , interferon/interferon inducer systemic medication suppress immune system within 4 week Visit 2 Treatment 5FU , imiquimod , diclofenac , photodynamic therapy within 2 cm treatment area 8 week prior visit 2 use systemic retinoids currently participate clinical trial female pregnant breastfeed know suspected able comply requirement protocol provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>